RK-01: A Think-Outside-The-Box Approach To Durable Glycemic Control
Type 2 diabetes continues to be an unmet medical need.
~50% of newly diagnosed patients experience primary failure with Metformin (the current standard of care) and secondary failure with second and third add-on drugs in the United States (Montvida, O. et al. Diabetes Care 2017).
Mitigation of the underlying pathophysiology of progresive deterioration of beta-cell function, the "Core defect" in all patients is underserved by current treatment options.
RK-01 is custom-designed and formulated to prevent primary and secondary failure by reducing the risk of insulin dependence.
Results obtained from animal studies as well as controlled clinical studies support the scientific rationale and the product concept.
Currently raising capital for a human PoC study to evaluate superiority of RK-01 over Metformin.
Submitted an IND application to the FDA in Q1-2018.